Komeno Masaharu, Akimoto Akira, Fujita Tsuneo, Katsube Nobuo
Fukui Safety Research Laboratories, Ono Pharmaceutical Co., Ltd., Sakai-Gun, Fukui, Japan.
J Pharmacol Sci. 2004 Nov;96(3):343-6. doi: 10.1254/jphs.scz040430. Epub 2004 Nov 12.
The effect of a selective inducible nitric oxide synthase inhibitor, ONO-1714 ((1S,5S,6R,7R)-7-chloro-3-imino-5-methyl-2-azabicyclo[4.1.0]heptane hydrochloride), on hemodialysis-related hypotension was investigated using a canine model of renal dysfunction. Renal dysfunction was induced in dogs by complete bilateral ligation of renal arteries. On performing hemodialysis with ultrafiltration, the blood pressure of the renal dysfunction dogs gradually decreased and persisted at reduced levels until completion. ONO-1714 ameliorated the hemodialysis-induced hypotension in the renal dysfunction dogs at a dose that did not influence blood pressure in non-hemodialysis dogs with normal renal function. The above findings indicated that ONO-1714 may elicit beneficial effects on hemodialysis-related hypotension.
使用犬类肾功能不全模型,研究了选择性诱导型一氧化氮合酶抑制剂ONO - 1714((1S,5S,6R,7R)-7 - 氯 - 3 - 亚氨基 - 5 - 甲基 - 2 - 氮杂双环[4.1.0]庚烷盐酸盐)对血液透析相关低血压的影响。通过双侧肾动脉完全结扎诱导犬类肾功能不全。在进行伴有超滤的血液透析时,肾功能不全犬的血压逐渐下降,并持续维持在较低水平直至透析结束。ONO - 1714以不影响肾功能正常的非血液透析犬血压的剂量改善了肾功能不全犬血液透析诱导的低血压。上述结果表明,ONO - 1714可能对血液透析相关低血压产生有益作用。